Last updated: February 24, 2026
What is NDC 62559-0306?
NDC 62559-0306 refers to Aletrocin, a prescription medication primarily used for ocular indications. The drug is distributed by Aegis Therapeutics, with approval in select markets for the treatment of diseases such as dry eye syndrome. It is a relatively new entrant in the ophthalmic drug space, approved by the FDA in 2021.
Market Overview
Current Market Size
The global ophthalmic drug market was valued at approximately $15 billion in 2022. The dry eye treatment segment alone accounts for about 20% of this market, or roughly $3 billion.
Competitive Landscape
Major competitors include:
- Restasis (cyclosporine, Allergan/AstraZeneca)
- Xiidra (lifitegrast, Novartis)
- Steroids and artificial tears
Aletrocin competes by offering a novel mechanism of action and potential for improved patient compliance.
Geographic Distribution
- United States: Largest market, driven by high prevalence of dry eye syndrome (estimated at 15% in adults aged 50+).
- Europe: Growing adoption, supported by similar prevalence rates.
- Asia-Pacific: Fastest growth, with emerging regulatory approvals.
Prescribing Trends
Physicians favor drugs with:
- Proven efficacy
- Favorable safety profiles
- Ease of administration
Aletrocin's innovativeness and safety profile support its early adoption in ophthalmology practices.
Price History and Current Pricing
Existing Pricing Data (Approximate)
| Product |
Typical Price (per unit) |
Formulation |
Market Status |
| Restasis |
$570 (per 30-day supply) |
0.05% ophthalmic emulsion |
Established, off-patent |
| Xiidra |
$600 (per 30-day supply) |
5% ophthalmic solution |
Approved since 2016 |
| Aletrocin |
$450 (estimate) |
0.2% ophthalmic solution |
Recently approved, limited data |
The initial estimate for Aletrocin’s price is based on comparable drugs, considering its novel formulation and early market entry.
Price Projection Assumptions
- Market penetration reaches 10% of dry eye segment within 3 years.
- Average price stabilizes at $475 per 30-day supply.
- Price declines to $400-$425 after patent exclusivity expires or generics enter around year 5.
- Reimbursement policies favor newer drugs with better safety profiles, supporting premium pricing initially.
Short-Term Forecast (Next 2 Years)
| Year |
Estimated Market Share |
Average Price |
Revenue Projection |
| 2023 |
2% of dry eye market |
$450 |
~$15 million |
| 2024 |
5% of dry eye market |
$470 |
~$45 million |
Long-Term Forecast (Next 5 Years)
| Year |
Estimated Market Share |
Average Price |
Revenue Projection |
| 2025 |
10% of dry eye market |
$470 |
~$100 million |
| 2027 |
15% of dry eye market |
$425 |
~$150 million |
Key Price Drivers and Risks
Price Drivers
- Improved formulation or delivery mechanism increases willingness to pay.
- Expanded indications, such as ocular surface diseases.
- Strong market uptake influenced by clinical data.
Risks to Price Stability
- Entry of generics post-patent expiration could reduce prices by 50% or more.
- Regulatory or safety issues may influence market acceptance.
- Competitive pressures from existing drugs with established pricing.
Regulatory and Patent Considerations
- Patent protection granted in 2022, valid until 2032.
- Exclusivity period supports premium pricing during initial years.
- Pending patent applications may extend exclusivity or block generics.
Conclusion
NDC 62559-0306, marketed as Aletrocin, enters an established ophthalmic segment dominated by high-priced drugs, with potential for competitive positioning due to its novel profile. Initial pricing around $450 per 30-day supply aligns with current market benchmarks. Projected revenue could reach $100–150 million within five years, assuming moderate market share growth. Price erosion is likely after patent expiration, with generics expected to emerge around 2032.
Key Takeaways
- Aletrocin targets a $3 billion dry eye segment with high unmet need.
- Initial prices are comparable to existing therapies, though innovation may command a premium.
- Market share growth depends on clinical adoption and reimbursement.
- Long-term pricing will decline after patent expiry and generic entry.
- Competitive landscape is dense; differentiation relies on safety and efficacy.
FAQs
Q1: What factors influence the initial pricing of Aletrocin?
The price depends on its clinical advantage, production costs, patient demand, and competitor pricing.
Q2: How quickly can Aletrocin gain market share?
Market share could reach 10% within 3 years if clinical results are positive and physicians adopt the drug.
Q3: When are generics likely to enter the market?
Patents expire around 2032, assuming no extension, after which generic competition may reduce prices significantly.
Q4: How does reimbursement impact pricing?
Reimbursement policies favor drugs with proven safety and efficacy, which can sustain higher prices initially.
Q5: What are the main risks for profit margins?
Patent challenges, safety concerns, or competition from generic versions could lower prices and margins.
References
[1] Market research report, "Global Ophthalmic Drugs Market," 2022.
[2] FDA approval documents for Aletrocin, 2021.
[3] Price comparison data, GoodRx, 2022.
[4] Industry analyst projections, PharmTech Insights, 2023.
[5] Patent and regulatory filings, U.S. Patent and Trademark Office, 2022.
